BioCentury | Aug 13, 2012
Strategy

Merck's new mark in HIV

...is a CYP3A inhibitor. There is at least one unlicensed CYP3A inhibitor in the clinic: Sequoia Pharmaceuticals Inc....
...Station, N.J. National Institutes of Health (NIH), Bethesda, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Sequoia Pharmaceuticals Inc....
BioCentury | Jan 2, 2012
Company News

J&J infectious news

...GmbH (Ingelheim, Germany), Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.), Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), Sequoia Pharmaceuticals Inc....
BioCentury | Dec 29, 2011
Company News

J&J not participating in Medicines Patent Pool

...in negotiations with Boehringer Ingelheim GmbH (Ingelheim, Germany), Bristol-Myers Squibb Co. (NYSE:BMY), Roche (SIX:ROG; OTCQX:RHHBY), Sequoia Pharmaceuticals Inc....
BioCentury | Aug 1, 2011
Company News

Boehringer Ingelheim, Bristol-Myers infectious news

...million in sales. The pool is already in negotiations with Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), Sequoia Pharmaceuticals Inc....
BioCentury | Dec 15, 2009
Politics & Policy

UNITAID approves HIV/AIDS patent pool

...Inc. (NASDAQ:GILD); Johnson & Johnson (NYSE:JNJ); Merck & Co. Inc. (NYSE:MRK); Pfizer Inc. (NYSE:PFE) and Sequoia Pharmaceuticals Inc....
BioCentury | Feb 23, 2009
Clinical News

SPI-452: Phase I data

...well tolerated. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Montreal. Sequoia Pharmaceuticals Inc....
BioCentury | Feb 23, 2009
Clinical News

SPI-452: Phase I data

...Johnson (NYSE:JNJ, New Brunswick, N.J.), and Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) markets Reyataz. Sequoia Pharmaceuticals Inc....
BioCentury | Nov 3, 2008
Clinical News

SPI-256: Phase I data

...Society of America joint meeting in Washington. Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) markets Norvir. Sequoia Pharmaceuticals Inc....
BioCentury | Mar 24, 2008
Company News

Basilea board of directors update

...Pharmaceutica AG (SWX:BSLN), Basel, Switzerland Business: Infectious, Dermatology Appointed: Steven Skolsky, president and CEO of Sequoia Pharmaceuticals Inc....
BioCentury | Dec 24, 2007
Clinical News

SPI-452: IND submitted

...quarter, Sequoia will begin a Phase I trial of SPI-452 in combination with HIV medications. Sequoia Pharmaceuticals Inc....
Items per page:
1 - 10 of 12
BioCentury | Aug 13, 2012
Strategy

Merck's new mark in HIV

...is a CYP3A inhibitor. There is at least one unlicensed CYP3A inhibitor in the clinic: Sequoia Pharmaceuticals Inc....
...Station, N.J. National Institutes of Health (NIH), Bethesda, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Sequoia Pharmaceuticals Inc....
BioCentury | Jan 2, 2012
Company News

J&J infectious news

...GmbH (Ingelheim, Germany), Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.), Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), Sequoia Pharmaceuticals Inc....
BioCentury | Dec 29, 2011
Company News

J&J not participating in Medicines Patent Pool

...in negotiations with Boehringer Ingelheim GmbH (Ingelheim, Germany), Bristol-Myers Squibb Co. (NYSE:BMY), Roche (SIX:ROG; OTCQX:RHHBY), Sequoia Pharmaceuticals Inc....
BioCentury | Aug 1, 2011
Company News

Boehringer Ingelheim, Bristol-Myers infectious news

...million in sales. The pool is already in negotiations with Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), Sequoia Pharmaceuticals Inc....
BioCentury | Dec 15, 2009
Politics & Policy

UNITAID approves HIV/AIDS patent pool

...Inc. (NASDAQ:GILD); Johnson & Johnson (NYSE:JNJ); Merck & Co. Inc. (NYSE:MRK); Pfizer Inc. (NYSE:PFE) and Sequoia Pharmaceuticals Inc....
BioCentury | Feb 23, 2009
Clinical News

SPI-452: Phase I data

...well tolerated. Data were presented at the Conference on Retroviruses and Opportunistic Infections in Montreal. Sequoia Pharmaceuticals Inc....
BioCentury | Feb 23, 2009
Clinical News

SPI-452: Phase I data

...Johnson (NYSE:JNJ, New Brunswick, N.J.), and Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) markets Reyataz. Sequoia Pharmaceuticals Inc....
BioCentury | Nov 3, 2008
Clinical News

SPI-256: Phase I data

...Society of America joint meeting in Washington. Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.) markets Norvir. Sequoia Pharmaceuticals Inc....
BioCentury | Mar 24, 2008
Company News

Basilea board of directors update

...Pharmaceutica AG (SWX:BSLN), Basel, Switzerland Business: Infectious, Dermatology Appointed: Steven Skolsky, president and CEO of Sequoia Pharmaceuticals Inc....
BioCentury | Dec 24, 2007
Clinical News

SPI-452: IND submitted

...quarter, Sequoia will begin a Phase I trial of SPI-452 in combination with HIV medications. Sequoia Pharmaceuticals Inc....
Items per page:
1 - 10 of 12